Physician profile
Christos S Mantzoros
NPI 1275512808
$242,959.20
in general payments reported to CMS, 2019-2025
16 companies · $124K in 2025
The $124K reported for 2025 was more than what 99% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,782 · 2020: $58K · 2021: $14K · 2022: $6,939 · 2023: $2,465 · 2024: $35K · 2025: $124K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $132K · Travel and Lodging: $14K · Honoraria: $7,650 · Food and Beverage: $3,891 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,049.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $132,063.50 |
| Travel and Lodging | $14,232.13 |
| Honoraria | $7,650.00 |
| Food and Beverage | $3,891.20 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,049.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coherus Oncology, INC. | $60,450.00 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39,970.59 | 2019-2025 | Jardiance |
| Regeneron Pharmaceuticals, INC. | $38,923.56 | 2019-2025 | |
| Amgen INC. | $30,456.92 | 2020-2025 | Tepezza, Parsabiv |
| Esperion Therapeutics, INC. | $19,095.30 | 2022-2025 | Nexlizet, Nexletol |
| Novo Nordisk INC | $18,270.18 | 2019-2025 | Ozempic, Wegovy |
| Madrigal Pharmaceuticals | $13,812.71 | 2024-2025 | Rezdiffra, Resmetirom |
| Olympus Corporation | $6,035.00 | 2024 | |
| Azurity Pharmaceuticals, INC. | $5,700.00 | 2025 | |
| Intercept Pharmaceuticals, INC. | $4,200.00 | 2020 | |
| Abbott Laboratories | $3,281.99 | 2023-2025 | Architect, Freestyle Libre 3 |
| Corcept Therapeutics | $2,446.59 | 2021-2023 | Korlym |
| Astrazeneca Pharmaceuticals Lp | $193.24 | 2019 | |
| Merck Sharp & Dohme LLC | $66.29 | 2022 | |
| Amarin Pharma, INC. | $35.00 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim International Gmbh | $21.83 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christos Mantzoros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.